Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.8 SEK | -1.07% | +3.94% | -12.82% |
Sales 2024 * | 1.88B 173M | Sales 2025 * | 3.16B 292M | Capitalization | 5.95B 548M |
---|---|---|---|---|---|
Net income 2024 * | 85M 7.84M | Net income 2025 * | 1.09B 101M | EV / Sales 2024 * | 3.1 x |
Net cash position 2024 * | 125M 11.56M | Net cash position 2025 * | 1.21B 111M | EV / Sales 2025 * | 1.5 x |
P/E ratio 2024 * |
26.2
x | P/E ratio 2025 * |
4.8
x | Employees | 217 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.29% |
Latest transcript on Calliditas Therapeutics AB
1 day | -1.07% | ||
1 week | +3.94% | ||
Current month | +0.73% | ||
1 month | -0.45% | ||
3 months | +0.36% | ||
6 months | +26.92% | ||
Current year | -12.82% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | -2.25% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 110.8 | -1.07% | 110,669 |
24-05-08 | 112 | +0.18% | 80,126 |
24-05-07 | 111.8 | +4.49% | 177,653 |
24-05-06 | 107 | +0.38% | 186,133 |
24-05-03 | 106.6 | -1.93% | 72,643 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.82% | 549M | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
+20.84% | 2.42B | |
-26.13% | 2.32B | |
+19.31% | 2.17B |
- Stock Market
- Equities
- CALTX Stock